Attached files
| file | filename |
|---|---|
| EX-10.26 - EXHIBIT 10.26 - CASI Pharmaceuticals, Inc. | tv489075_ex10-26.htm |
| EX-31.1 - EXHIBIT 31.1 - CASI Pharmaceuticals, Inc. | tv489075_ex31-1.htm |
| EX-32.2 - EXHIBIT 32.2 - CASI Pharmaceuticals, Inc. | tv489075_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - CASI Pharmaceuticals, Inc. | tv489075_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - CASI Pharmaceuticals, Inc. | tv489075_ex31-2.htm |
| 10-K - FORM 10-K - CASI Pharmaceuticals, Inc. | tv489075_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements of CASI Pharmaceuticals, Inc. on Forms S-8 (File Nos. 333-68048, 333-188042, 333-101617 and 333-222043) and Forms S-3 (File Nos. 333-80193, 333-84907, 333-76824, 333-104380, 333-110604, 333-122309, 333-133190, 333-132715, 333-151542, 333-167754, 333-182803, 333-200927, 333-214889, 333-222046, and 333-222701) of our report, dated March 29, 2018 on our audits of the consolidated financial statements of CASI Pharmaceuticals, Inc., as of December 31, 2017 and 2016 and for the years then ended, included in this Annual Report on Form 10-K of CASI Pharmaceuticals, Inc. for the year ended December 31, 2017.
| /s/ CohnReznick LLP | |
| Roseland, New Jersey | |
| March 29, 2018 |